We’re contributing to a healthier future with viral vector manufacturing.
Cell and gene therapies are transforming human health and new breakthrough medicines can be provided to patients. With this progression, the worldwide demand for viral vectors has risen enormously.
Novartis is offering the production of viral vectors for cell and gene therapy or vaccines and contributing to a healthier future with E2E viral vector manufacturing. A state-of-the-art facility is available for the manufacturing of:
- Adeno-associated viruses (AAV)
- Adenovirus (AV)
An experienced team, upscaling capabilities and highest quality standards make Novartis an attractive partner for viral vector manufacturing. The Novartis Quality Management System ensures regulatory compliance and the highest possible product quality.